The American Society of Clinical Oncology earlier this week published a proposed framework for assessing the value of new cancer treatments.
The House and Senate appropriations committees earlier this week passed parallel spending bills that would boost NIH budgets while eliminating the Agency for Healthcare Research Quality, a $465 million agency that plays a central role in the implementation of President Barack Obama's health care law.
FDA approved the Ventana ALK (D5F3) CDx Assay as a companion diagnostic to aid in the identification of patients for Pfizer's targeted therapy, Xalkori (crizotinib).
ELI LILLY AND COMPANY announced two research collaborations.
THE AGENCY FOR HEALTHCARE RESEARCH AND QUALITY plans to fund three centers of excellence to study how high-performing health care systems promote evidence-based practices in delivering care. The grants were announced at AcademyHealth's Annual Research Meeting in Minneapolis by Richard Kronick, director of AHRQ.
JOHN ZAIA was named director of the Center for Gene Therapy within City of Hope's Hematologic Malignancies and Stem Cell Transplantation Institute.
The European Commission has granted marketing authorization for Gardasil 9.
JOHN SAMPSON was named chair of the new Department of Neurosurgery within the Duke University School of Medicine.
The Cancer Prevention and Research Institute of Texas has provided more than 2 million cancer prevention services to Texans across all 254 counties in the state, the institute announced June 16.
House and Senate sponsors have reintroduced the Cancer Treatment Parity Act, a bill that would require insurers to provide coverage for oral anticancer drugs on terms no less favorable than coverage for intravenous chemotherapy.
